Trial Profile
Evaluation of Ruxolitinib and Azacytidine Combination as a Therapy for Patients With Myelofibrosis and Myelodysplastic Syndrome/ Myeloproliferative Neoplasm
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Jan 2024
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Ruxolitinib (Primary)
- Indications Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Essential thrombocythaemia; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders; Polycythaemia vera
- Focus Therapeutic Use
- 12 Dec 2023 Results( data cutoff July 15, 2023 , n=52 ) evaluating the use of RUX-AZA in newly diagnosed or previously treated MDS/ MPN, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 04 Apr 2023 Planned End Date changed from 1 Mar 2024 to 30 Apr 2025.
- 04 Apr 2023 Planned primary completion date changed from 1 Mar 2023 to 30 Apr 2025.